We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNBX
276
DELISTED
BNB PLUS CORP
BNBX
– –
-1
Closed -$1.66M
RMTI icon
277
Rockwell Medical
RMTI
$27.6M
$286K 0.01%
+161
New +$205K
BLPH
278
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$283K 0.01%
2,382
+382
+19% +$51.9K
AMRN
279
PUT
Amarin Corp
AMRN
$300M
$275K 0.01%
+56
New +$2.52K
ATHX
280
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$272K 0.01%
90
-24
-21% -$932
CBAY
281
DELISTED
Cymabay Therapeutics
CBAY
$269K 0.01%
100,000
– –
THOR
282
PUT
DELISTED
THORATEC CORPORATION
THOR
$267K 0.01%
+60
New +$2.63K
XNPT
283
CALL
DELISTED
XENOPORT, INC.
XNPT
$266K 0.01%
434
+297
+217% +$1.94K
NSPR icon
284
InspireMD
NSPR
$31.8M
– –
-1
Closed -$1.77M
TNXP icon
285
Tonix Pharmaceuticals
TNXP
$153M
– –
0
– –
SCPX
286
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
-1
Closed -$1.83M
TEVA icon
287
Teva Pharmaceuticals
TEVA
$40.3B
$247K 0.01%
+4,173
New +$257K
AR icon
288
Antero Resources
AR
$10.9B
$246K 0.01%
+8,580
New +$341K
IPCI
289
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$243K 0.01%
83
-59
-42% -$1.78K
NBSE
290
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$226K 0.01%
225
-263
-54% -$284K
KITE
291
DELISTED
Kite Pharma, Inc.
KITE
$224K 0.01%
+3,672
New +$210K
ARDX icon
292
Ardelyx
ARDX
$1.25B
$220K 0.01%
13,757
-98,417
-88% -$1.24M
DYAX
293
PUT
DELISTED
DYAX CORPORATION
DYAX
$200K 0.01%
75
-377
-83% -$9.99K
KERX
294
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$188K 0.01%
188
-42
-18% -$450
OCGN icon
295
Ocugen
OCGN
$406M
$178K 0.01%
458
– –
ACHN
296
DELISTED
Achillion Pharmaceuticals
ACHN
$167K 0.01%
18,835
-94,869
-83% -$897K
PVCT.WS
297
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
$164K 0.01%
+749,337
New +$156K
GBSN
298
DELISTED
GREAT BASIN SCIENTIFIC INC COM PAR $.0001 NEW
GBSN
– –
0
– –
IMNN icon
299
PUT
Imunon
IMNN
$6.43M
– –
0
– –
SEEL
300
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
10 11
12
13 14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.